Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer

John O. Schorge, Richard D. Drake, Hang Lee, Steven J. Skates, Ramababu Rajanbabu, David S. Miller, Jae Hoon Kim, Daniel W. Cramer, Ross S. Berkowitz, Samuel C. Mok

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Purpose: CA125 is currently the only tumor marker to have a validated role in the postoperative monitoring of ovarian cancer. Osteopontin (OPN) is a putative plasma biomarker that was recently identified using high-through-put cDNA microarray technology. The purpose of this study was to test the hypothesis that OPN is a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer. Experimental Design: Thirty-eight ovarian cancer patients had a single pretreatment blood sample and 200 post-operative specimens were prospectively collected during chemotherapy and follow-up. OPN measurements were performed using an enzyme-linked immunoassay, and CA125 levels were concurrently obtained. Wilcoxon's signed rank-sum test was used to perform paired comparisons between pretreatment and postoperative OPN and CA125 measurements. Longitudinal mixed effects polynomial models were used to determine whether OPN and CA125 levels correlated with the development of recurrent ovarian cancer. Results: The median pretreatment OPN level was 178 ng/ml (range, 12-3468) and the median CA125 measurement was 812 units/ml (range, 12-81,500). There was a trend for OPN levels to decline after treatment was initiated (P = 0.07), but decreasing CA125 measurements were more consistently observed (P = 0.0009). The quadratic functional trends of OPN and CA125 were each highly significant (P < 0.0001). Although inferior to CA125 in predicting clinical response to therapy, OPN rose earlier in 90% (95% confidence interval, 56-100%) of the patients developing recurrent disease (median lead time, 3 months). Conclusions: OPN may be a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer.

Original languageEnglish
Pages (from-to)3474-3478
Number of pages5
JournalClinical Cancer Research
Volume10
Issue number10
DOIs
Publication statusPublished - 2004 May 15

Fingerprint

Osteopontin
Ovarian Neoplasms
Matched-Pair Analysis
Statistical Models
Tumor Biomarkers
Nonparametric Statistics
Oligonucleotide Array Sequence Analysis
Immunoenzyme Techniques
Research Design
Biomarkers
Confidence Intervals
Technology
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Schorge, J. O., Drake, R. D., Lee, H., Skates, S. J., Rajanbabu, R., Miller, D. S., ... Mok, S. C. (2004). Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clinical Cancer Research, 10(10), 3474-3478. https://doi.org/10.1158/1078-0432.CCR-03-0365
Schorge, John O. ; Drake, Richard D. ; Lee, Hang ; Skates, Steven J. ; Rajanbabu, Ramababu ; Miller, David S. ; Kim, Jae Hoon ; Cramer, Daniel W. ; Berkowitz, Ross S. ; Mok, Samuel C. / Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 10. pp. 3474-3478.
@article{06f91749763547229f766e54e443da87,
title = "Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer",
abstract = "Purpose: CA125 is currently the only tumor marker to have a validated role in the postoperative monitoring of ovarian cancer. Osteopontin (OPN) is a putative plasma biomarker that was recently identified using high-through-put cDNA microarray technology. The purpose of this study was to test the hypothesis that OPN is a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer. Experimental Design: Thirty-eight ovarian cancer patients had a single pretreatment blood sample and 200 post-operative specimens were prospectively collected during chemotherapy and follow-up. OPN measurements were performed using an enzyme-linked immunoassay, and CA125 levels were concurrently obtained. Wilcoxon's signed rank-sum test was used to perform paired comparisons between pretreatment and postoperative OPN and CA125 measurements. Longitudinal mixed effects polynomial models were used to determine whether OPN and CA125 levels correlated with the development of recurrent ovarian cancer. Results: The median pretreatment OPN level was 178 ng/ml (range, 12-3468) and the median CA125 measurement was 812 units/ml (range, 12-81,500). There was a trend for OPN levels to decline after treatment was initiated (P = 0.07), but decreasing CA125 measurements were more consistently observed (P = 0.0009). The quadratic functional trends of OPN and CA125 were each highly significant (P < 0.0001). Although inferior to CA125 in predicting clinical response to therapy, OPN rose earlier in 90{\%} (95{\%} confidence interval, 56-100{\%}) of the patients developing recurrent disease (median lead time, 3 months). Conclusions: OPN may be a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer.",
author = "Schorge, {John O.} and Drake, {Richard D.} and Hang Lee and Skates, {Steven J.} and Ramababu Rajanbabu and Miller, {David S.} and Kim, {Jae Hoon} and Cramer, {Daniel W.} and Berkowitz, {Ross S.} and Mok, {Samuel C.}",
year = "2004",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-03-0365",
language = "English",
volume = "10",
pages = "3474--3478",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

Schorge, JO, Drake, RD, Lee, H, Skates, SJ, Rajanbabu, R, Miller, DS, Kim, JH, Cramer, DW, Berkowitz, RS & Mok, SC 2004, 'Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer', Clinical Cancer Research, vol. 10, no. 10, pp. 3474-3478. https://doi.org/10.1158/1078-0432.CCR-03-0365

Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. / Schorge, John O.; Drake, Richard D.; Lee, Hang; Skates, Steven J.; Rajanbabu, Ramababu; Miller, David S.; Kim, Jae Hoon; Cramer, Daniel W.; Berkowitz, Ross S.; Mok, Samuel C.

In: Clinical Cancer Research, Vol. 10, No. 10, 15.05.2004, p. 3474-3478.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer

AU - Schorge, John O.

AU - Drake, Richard D.

AU - Lee, Hang

AU - Skates, Steven J.

AU - Rajanbabu, Ramababu

AU - Miller, David S.

AU - Kim, Jae Hoon

AU - Cramer, Daniel W.

AU - Berkowitz, Ross S.

AU - Mok, Samuel C.

PY - 2004/5/15

Y1 - 2004/5/15

N2 - Purpose: CA125 is currently the only tumor marker to have a validated role in the postoperative monitoring of ovarian cancer. Osteopontin (OPN) is a putative plasma biomarker that was recently identified using high-through-put cDNA microarray technology. The purpose of this study was to test the hypothesis that OPN is a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer. Experimental Design: Thirty-eight ovarian cancer patients had a single pretreatment blood sample and 200 post-operative specimens were prospectively collected during chemotherapy and follow-up. OPN measurements were performed using an enzyme-linked immunoassay, and CA125 levels were concurrently obtained. Wilcoxon's signed rank-sum test was used to perform paired comparisons between pretreatment and postoperative OPN and CA125 measurements. Longitudinal mixed effects polynomial models were used to determine whether OPN and CA125 levels correlated with the development of recurrent ovarian cancer. Results: The median pretreatment OPN level was 178 ng/ml (range, 12-3468) and the median CA125 measurement was 812 units/ml (range, 12-81,500). There was a trend for OPN levels to decline after treatment was initiated (P = 0.07), but decreasing CA125 measurements were more consistently observed (P = 0.0009). The quadratic functional trends of OPN and CA125 were each highly significant (P < 0.0001). Although inferior to CA125 in predicting clinical response to therapy, OPN rose earlier in 90% (95% confidence interval, 56-100%) of the patients developing recurrent disease (median lead time, 3 months). Conclusions: OPN may be a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer.

AB - Purpose: CA125 is currently the only tumor marker to have a validated role in the postoperative monitoring of ovarian cancer. Osteopontin (OPN) is a putative plasma biomarker that was recently identified using high-through-put cDNA microarray technology. The purpose of this study was to test the hypothesis that OPN is a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer. Experimental Design: Thirty-eight ovarian cancer patients had a single pretreatment blood sample and 200 post-operative specimens were prospectively collected during chemotherapy and follow-up. OPN measurements were performed using an enzyme-linked immunoassay, and CA125 levels were concurrently obtained. Wilcoxon's signed rank-sum test was used to perform paired comparisons between pretreatment and postoperative OPN and CA125 measurements. Longitudinal mixed effects polynomial models were used to determine whether OPN and CA125 levels correlated with the development of recurrent ovarian cancer. Results: The median pretreatment OPN level was 178 ng/ml (range, 12-3468) and the median CA125 measurement was 812 units/ml (range, 12-81,500). There was a trend for OPN levels to decline after treatment was initiated (P = 0.07), but decreasing CA125 measurements were more consistently observed (P = 0.0009). The quadratic functional trends of OPN and CA125 were each highly significant (P < 0.0001). Although inferior to CA125 in predicting clinical response to therapy, OPN rose earlier in 90% (95% confidence interval, 56-100%) of the patients developing recurrent disease (median lead time, 3 months). Conclusions: OPN may be a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=2542434974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542434974&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-03-0365

DO - 10.1158/1078-0432.CCR-03-0365

M3 - Article

C2 - 15161704

AN - SCOPUS:2542434974

VL - 10

SP - 3474

EP - 3478

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -

Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clinical Cancer Research. 2004 May 15;10(10):3474-3478. https://doi.org/10.1158/1078-0432.CCR-03-0365